Iovance Biotherapeutics Investor Presentation — April 2019

Document content

© 2019, Iovance Biotherapeutics, Inc.Corporate PresentationThis presentation contains “forward -looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Compan y,” “we,” “us,” or “our”). We may, in some cases, use

terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “ma y,”“could,” “might,” “will,” “should” or other words that convey

uncertainty of future events or outcomes to identify these forward -looking statements. The forward -looking statements include, b ut are not limited to, risks and uncertainties relating to

the success, timing, projected enrollment, manufacturing capabilities, and cost of our ongoing clinical trials and anticipate d clinical trials for our current product candidates (including

both Company -sponsored and collaborator -sponsored trials in the U.S. and Europe), such as statements regarding the timing of ini tiation and completion of these trials or cohorts within

these trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulat oryauthority approval of, or other action with respect to, our

product candidates; the strength of Company’s product pipeline; the successful implementation of the Company’s research and d evelopment programs and collaborations; the success of

the Company’s manufacturing, license or development agreements; the acceptance by the market of the Company’s product candida tes, if approved; and other factors, including general

economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause a ctual results and developments to be materially different

from those expressed in or implied by such statements. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in the Company’s

business, including, without limitation: the FDA may not agree with the Company’s interpretation of the results of its clinic al trials; later developments with the FDA that may be

inconsistent with already completed FDA meetings; the preliminary clinical results, including efficacy and safety results, fr om ongoing Phase 2 studies described above may not be

reflected in the final analyses of these trials including new cohorts within these trials; the results obtained in the Compan y’songoing clinical trials, such as the studies and trials referred

to in this presentation, may not be indicative of results obtained in future clinical trials or supportive of product approva l; regulatory authorities may potentially delay the timing of FDA

or other regulatory authority approval of, or other action with respect to, the Company’s product candidates (specifically, t he Company’s description of FDA interactions are subject to